Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A425ME | ISIN: US80512Q6008 | Ticker-Symbol: 80W0
München
13.05.26 | 10:11
3,400 Euro
0,00 % 0,000
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXENTIS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
NEXENTIS TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur NEXENTIS TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:30Nexentis subsidiary achieves drug discovery milestone1
13:22Nexentis-Tochter meldet Meilenstein in der Wirkstoffforschung1
13:12Nexentis Technologies Inc.: Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone59MITOLINE,-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis...
► Artikel lesen
05.05.Nexentis subsidiary receives U.S. trademark for drug platform2
05.05.Nexentis Technologies Inc.: Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE224Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets...
► Artikel lesen
NEXENTIS TECHNOLOGIES Aktie jetzt für 0€ handeln
06.04.Nexentis Technologies führt Reverse-Aktiensplit im Verhältnis 1:7 an der NASDAQ durch3
06.04.Nexentis Technologies Inc. - 8-K, Current Report-
31.03.Nexentis Technologies Inc. - 10-K, Annual Report-
17.03.Nexentis Technologies Inc. - 8-K, Current Report2
13.03.Nexentis Launches Corporate Website2
13.03.Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform1
25.02.N2OFF, Inc. - 8-K, Current Report1
25.02.N2OFF Inc.: N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company742New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve...
► Artikel lesen
20.02.Plantify Foods Inc (2): Plantify holder N2OFF's shareholdings decrease to 14.6%3
19.02.Plantify Foods, Inc.: N2OFF, Inc. Provides Early Warning Disclosure3
12.02.N2OFF Inc.: MitoCareX Bio Reports Successful Results in Vitro: MITOLINE-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases208MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
02.02.N2OFF Inc.: In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions1
22.01.N2OFF Inc.: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform242MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
15.01.N2OFF Inc.: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions2
12.01.N2OFF vergütet Berater für Investor Relations mit 35.000 Aktien2
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1